MA
PGNX

MUFG Americas’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

MUFG Americas’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-134
Closed -$1K – 1068
2017
Q4 		$1K Sell
134
-79
-37% -$480 ﹤0.01% 1045
2017
Q3 		$2K Hold
213
– – ﹤0.01% 1076
2017
Q2 		$1K Hold
213
– – ﹤0.01% 1126
2017
Q1 		$2K Hold
213
– – ﹤0.01% 1080
2016
Q4 		$2K Sell
213
-223
-51% -$1.65K ﹤0.01% 1045
2016
Q3 		$3K Sell
436
-224
-34% -$1.35K ﹤0.01% 1065
2016
Q2 		$3K Hold
660
– – ﹤0.01% 1082
2016
Q1 		$3K Buy
+660
New +$2.94K ﹤0.01% 1090

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

MUFG Americas's PGNX Position: Q1 2018 in Review

MUFG Americas sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 134 shares — an estimated $1K sold.

MUFG Americas first reported a position in PGNX in Q1 2016 and held it in 8 quarters. The position peaked at $3K in Q3 2016. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • MUFG Americas reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • MUFG Americas sold 134 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $1K.
  • MUFG Americas first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 8 quarters.
  • MUFG Americas's Progenics Pharmaceuticals Inc position peaked at $3K in Q3 2016.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on MUFG Americas's 13F filing for Q1 2018, filed 7 May 2018.